Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16999929 | 0.92 | ESR2 (0.34) | ESR1ESR2CYP3A4PTGS1ALOX15 | |
| SCHEMBL16993464 | 0.88 | ESR1 (0.34) | ESR1ESR2ALOX15ALOX12PTPN1 | |
| SCHEMBL16999939 | 0.88 | CYP3A4 (0.42) | ESR1ESR2CYP3A4PTGS1CYP2D6 | |
| SCHEMBL16999930 | 0.87 | TUBB4A (0.43) | CYP3A4PTGS1CYP2D6PTPN1 | |
| SCHEMBL2731372 | 0.81 | HTR2A (0.34) | ESR1ESR2CYP3A4PTGS1CYP2D6 | |
| SCHEMBL10098029 | 0.81 | HTR2A (0.34) | ESR1ESR2CYP3A4PTGS1CYP2D6 | |
| SCHEMBL30362760 | 0.81 | HTR2A (0.34) | ESR1ESR2CYP3A4PTGS1CYP2D6 | |
| SCHEMBL15953600 | 0.81 | HTR2A (0.34) | ESR1ESR2CYP3A4PTGS1CYP2D6 | |
| SCHEMBL2716699 | 0.81 | KDM1A (0.41) | CYP3A4PTGS1CYP2D6PTPN1 | |
| SCHEMBL15954687 | 0.81 | KDM1A (0.41) | CYP3A4PTGS1CYP2D6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | Kazia Therapeutics Limited (AU) | 2019-08-06 | — | — | US | disclosed |
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | Kazia Therapeutics Limited (AU) | 2019-08-06 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| EP-2953938-B1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Novogen ltd (AU) | 2017-08-02 | — | — | EP | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| WO-2015117202-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | NOVOGEN LIMITED (AU) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, BRAP, EP300 | ESR1 2369/4885ESR2 2681/4885CYP3A4 145/4885 |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, VHL, NQO1 | ESR1 399/4885ESR2 1299/4885CYP3A4 57/4885 |
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | BRCA1, BRAP, EP300 | ESR1 2369/4885ESR2 2681/4885CYP3A4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.